|LETTER TO EDITOR
|Year : 2021 | Volume
| Issue : 1 | Page : 172
New COVID-19 Variant, VUI-202012/01: Molecular change, epitope alteration, and implication for vaccine efficacy
Beuy Joob1, Viroj Wiwanitkit2
1 Department of Community Medicine, Private Academic Consultant, Bangkok, Thailand
2 Honoary Professor, Dr. D. Y. Patil University, Pune, India
|Date of Submission||21-Dec-2020|
|Date of Acceptance||22-Dec-2020|
|Date of Web Publication||14-Dec-2021|
Sanitation 1 Medical Academic Center, Bangkok
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Joob B, Wiwanitkit V. New COVID-19 Variant, VUI-202012/01: Molecular change, epitope alteration, and implication for vaccine efficacy. Int J Prev Med 2021;12:172
|How to cite this URL:|
Joob B, Wiwanitkit V. New COVID-19 Variant, VUI-202012/01: Molecular change, epitope alteration, and implication for vaccine efficacy. Int J Prev Med [serial online] 2021 [cited 2022 Jan 19];12:172. Available from: https://www.ijpvmjournal.net/text.asp?2021/12/1/172/332552
COVID-19 is the new emerging coronavirus infection. The pandemic results in more than 75,000,000 people around the world (data on December 21, 2020). In clinical genetic, impact of genetic change on the infection is an interesting issue. The mutation might occur with the SARSCoV2 virus molecule. Recently, there is a report on new COVID-19 variant, VUI-202012/01. This new strain was firstly observed in UK and the relationship with increased transmissibility property is reported. The main genetic change is the genetic mutation N501Y inside the spike glycoprotein's receptor-binding domain, which is important molecular part binding to the ACE2 receptor in humans. In vaccinology, the impact of the mutation on vaccine efficacy is an important question.
Here, the authors use a standard bioinformatics analysis, as used in previous reports,, for assessing the effect of molecular change in the VUI-202012/01. The online tool is accessible via http://www.syfpeithi.de/bin/MHCServer.dll/EpitopePrediction.htm. According to the analysis, there is a change of epitope pattern. At the mutation part, the identified epitope sequence change from “487F Q P T N G V G Y” in naïve case to “515C G P K K S T N L” in VUI-202012/01. It might expect that the VUI-202012/01 will be the new problem to prevent the successful COVID-19 containment by the newly available COVID-19 vaccines.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Joob B, Wiwanitkit V. Epitope finding in 2019 novel coronavirus (2019-nCoV): The first world report. Asian Pac J Trop Med 2020;13:187-8. [Full text]
Wiwanitkit V, Wiwanitkit S. T cell epitopes within envelope glycoprotein of Ebola virus: The clue for vaccine development. Ann Trop Med Public Health 2015;8:16. [Full text]